Australia's most trusted
source of pharma news
Posted 16 February 2026 AM
The number of biosimilars subsidised on the PBS in 2024-25 grew by almost 50 per cent compared to the previous year, but the total cost to government remained almost the same, suggesting originator brands successfully defended their market share.
Pharma in Focus compared the 2023-24 financial year and 2024-25 financial year PBS Expenditure and Prescription reports to analyse the change in the cost to government of biosimilar products over the two years, although the data does not include drugs funded under efficient funding of chemotherapy.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.